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ABSTRACT 
Despite many advances in antenatal care, twin pregnancies still experience more adverse 
outcomes, in particular higher perinatal mortality and morbidity. They also pose a multitude 
of challenges and controversies as outlined in this paper. Moreover, they are less likely to be 
included in clinical trials. Many issues on classification and management remain under 
debate. Efforts on standardising diagnostic criteria, monitoring protocols, management and 
outcome reporting are likely to reduce their perinatal risks. The top 10 most important 
research uncertainties related to multiple pregnancies have been identified by both clinicians 
and patients. More robust research in the form of randomised trials and large well-conducted 
prospective cohort studies are needed to address these controversies. 
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Introduction 
The incidence of multiple pregnancies has increased substantially in the last few decades. 
This increase is most likely to be related to the rise in the use of assisted reproductive 
techniques1. These pregnancies not only contributes to a disproportionate number of 
cerebral palsy2, stillbirths3, 4, and neonatal morbidity and mortality5, it also poses an 
increased risk of maternal complications such as hypertensive disorders6, thereby leading to 
increased healthcare costs, largely due to the high rate of neonatal unit (NNU) admissions7. 
Despite this, multiple pregnancies are often excluded from research studies, with only 8% of 
trials into fetal growth restriction (FGR), 17% of pre-eclampsia and 2% of diabetes research 
that included multiple pregnancies over the last 7 years. Furthermore, most of the 
recommendations in national and international guidelines on the management of multiple 
pregnancies lack high quality robust evidence8.  
In this paper, we aim to outline the controversies in the screening, assessment, diagnosis, 
and management of multiple pregnancies. 
 
Controversies in the screening for aneuploidy in twin pregnancies 
First trimester screening for common aneuploidies in twins can take place using the 
combined test (including maternal age, nuchal translucency (NT), serum PAPP-A and β-
hCG levels), or using the maternal age and NT measurements alone9,10. A meta-analysis 
has shown that the detection rate (DR) for trisomy 21 in twins was similar to singletons (86% 
in dichorionic (DC) and 87% in monochorionic (MC) twins, compared to 89% in singletons), 
with a false positive rate (FPR) of 5%11. In those who book their pregnancy in the second 
trimester, a quadruple test is only available for the detection of trisomy 21, with a DR of 80% 
and 40-50% for MC and DC twins respectively, for a standard screen positive rate of 3%10.  
Non-invasive prenatal testing (NIPT) is becoming increasingly common, and in singletons, 
has a DR of >99%, with a FPR of 0.13%12. In twins, aneuploidies are often discordant, and 
unequal contribution of the fetuses to cell-free DNA (cfDNA) can lead to a false negative 
result, in cases where the normal twin contributes to a higher fetal fraction13, 14. Furthermore, 
NIPT had a higher failure rate in twin pregnancies as dichorionicity, conception by in-vitro 
fertilisation (IVF), and higher maternal weight were significant predictors in the failure of 
NIPT, with other predictors being nulliparity and increased maternal age13,15. Few studies 
have investigated the validity of NIPT in twins. For trisomy 21, the reported DR ranges from 
94 to 100%, with a failure rate of 2.9-9.4%12–14,16. In trisomy 18 and 13, the DR was 60% in 
twins14, compared to 97.9% and 99% in singletons12, respectively, but these results were 
limited by the small numbers of positive findings. Single twin demise can also render the 
results of the NIPT unreliable. As these early deaths are more likely to be aneuploid, it can 
lead to discordant results, due to the continued release of cfDNA of the demised twin into the 
maternal circulation17,18.  
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Screening for aneuploidies in twins therefore offers promising results, however, higher failure 
rates and discordance can be seen in twins, and further studies with larger numbers of 
aneuploidies are required to ascertain the validity of these tests. 
 
Controversies in the assessment of fetal growth in twin pregnancies 
Twins are known to have lower birthweight than singletons19, and due to their higher risk of 
perinatal complications, in particular FGR, more stringent surveillance using ultrasound is 
required20,21. Recent research have found that twins have a different growth trajectory than 
singletons, where in DC twins, the growth is lower from 30 weeks compared to singletons, 
and MC twins are generally smaller than both DC twins and singletons throughout the 
gestations22. Yet, current practice continues to use singleton growth charts, which can lead 
to an overdiagnosis of FGR in twins, and unnecessary iatrogenic preterm deliveries. Despite 
previous evidence which stated that twins diagnosed as FGR according to singleton growth 
charts still had a higher perinatal mortality rate than singletons, this was only the case in MC 
but not in DC twins23. Twin-specific growth charts have now been designed based on their 
normal reference ranges and are readily available for use. It has been shown that these 
charts do not increase the incidence of stillbirth, but do in fact reduce the number of twins 
diagnosed as FGR compared to those diagnosed by customised singleton charts (7.1% vs 
12.8%, respectively)24.  
It is recommended that DC twins undergo 4 weekly scans for growth surveillance from 24 
weeks, and MC twins 2 weekly from 16 weeks9,21. Fetal Doppler measurements such as 
umbilical artery (UA) and middle cerebral artery (MCA) pulsatility index (PI) as well as MCA 
peak systolic velocity (PSV) can allow for detection of placental insufficiency, twin-anaemia-
polycythaemia sequence (TAPS), and fetal decompensation in twin-twin-transfusion 
syndrome (TTTS) and FGR, and is therefore recommended by the International Society of 
Ultrasound in Obstetrics and Gynaecology (ISUOG) to be performed at each routine scan9. 
However, other guidelines state that these measurements should only be performed in high-
risk pregnancies21,25.  
Various thresholds have been used to classify estimated fetal weight (EFW) discordance. 
The Southwest Thames Obstetric Research Collaborative (STORK) found that the 95th 
centile of EFW discordance for DC twins was 18.3% at 20 weeks, increasing to 21.9% by 30 
weeks, and in MC twins, 22.2% at 20 weeks, and 25.4% at 30 weeks26. Therefore, any 
discordance within these values is considered as a part of the normal trajectory. Similarly, 
D’Antonio et al found that an EFW discordance of ≥25% was associated with a significant 
increase in perinatal loss (area under the curve (AUC) 0.72, 95% confidence interval (CI) 
0.65-0.80)27. However, a recent meta-analysis showed that risk of stillbirth increased from a 
discordance of ≥15% in DC twins (odds ratio (OR) 9.8, 95% CI 3.9-29.4) and ≥20% in MC 
twins (OR 2.8, 95% CI 1.3-5.8), with an increased risk of neonatal death (NND) from ≥25% 
in MC twins (OR 4.66, 95% CI 1.8-12.4)28. Moreover, one size does not fit all, as the optimal 
cut-off for prediction of single intrauterine death (sIUD) differs with increasing gestational age 
(48% at 28-30+6 weeks, 20% at 31-33+6 weeks, and 14% at 34-36+6 weeks)29. Therefore, 
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a decision for delivery should not be based on EFW discordance alone, but on a 
combination of gestation, chorionicity, Doppler indices, and antenatal complications.  
The controversies in fetal growth assessment are improving through the development of 
twin-specific growth charts and national guidelines, but can be further unified by 
standardising twin growth chart utilisation, routine Doppler measurements, classification of 
EFW discordance, and indications for delivery. 
 
Controversies in the management of fetal growth restriction in twin pregnancies 
Selective FGR (sFGR) is associated with an increased perinatal morbidity and mortality, as 
well as neurological sequelae in both the small for gestational-age (SGA) and appropriate for 
gestational-age (AGA) twins28,30. Until recently, there have been numerous discrepancies 
amongst clinicians and researchers on the diagnostic criteria of sFGR. ISUOG proposed that 
DC twins were classified as sFGR if the EFW of one twin was <10th centile, whilst in MC 
twins, if the EFW of one twin was <10th centile and the EFW discordance was >25%9. An 
expert consensus using the Delphi procedure aimed to unify diagnosis was since developed, 
where it concluded that in both MC and DC twins, an EFW <3rd centile in one twin would 
classify as sFGR. Additionally, DC twins satisfied the diagnosis if 2 of the 3 parameters were 
met: EFW <10th centile, EFW discordance ≥25%, or UA PI >95th centile, and in MC twins, 2 
of the 4 parameters: EFW <10th centile, AC <10th centile, EFW discordance ≥25%, or UA PI 
>95th centile (Figure 1)31. Research comparing these diagnostic criteria have noted a 
variation in incidence, thus supporting the use of the standardised Delphi criteria32.  
Due to the increased perinatal morbidity and mortality posed by FGR in twins, it is 
paramount that clinicians are aware of its presentation and a robust guidance is in place to 
aid its screening and detection. Recent updates to the National Institute of Clinical 
Excellence (NICE) guidelines have recommended serial growth scans as described above, 
together with deepest vertical pocket measurements (DVP), an EFW discordance to be 
calculated at each scan, and UA Dopplers to be performed together with weekly scans if an 
EFW discordance was >20% or the EFW of one twin was <10th centile21. Further progression 
to a discordance ≥25% should prompt a referral to a tertiary fetal medicine unit.  
Gratacós et al classified sFGR in MC twins according to UA Doppler end-diastolic-flow 
(EDF) in the smaller twin, which have different clinical evolution and outcomes33. Studies 
have looked into the progression and overall survival rates of each type in order to aid 
counselling and management. Type I (positive EDF) is associated with a generally good 
outcome, with a progression rate of up to 26%34. Type II (persistent absent/reversed EDF) 
has the least favourable outcome, with progression rates as high as 90%33. Type III 
(intermittent absent/reversed EDF) has a lower progression rate, but due to the variable AA 
anastomoses, has a higher risk of sudden intrauterine demise (IUD) or acute TTTS33 (Figure 
2). Due to the higher risks of preterm delivery (68%), IUD (15%), and neurological sequelae 
(26%) to the co-twin in the event of demise in the FGR twin if conservatively managed30, 
prenatal intervention in the form of selective termination are more likely considered in severe 
cases, especially before 26 weeks9,35,36. A recent meta-analysis compared the outcomes 
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following expectant management, fetoscopic laser photocoagulation, and selective 
termination according to Gratacós classification. In type I sFGR, 3%, 16.7%, and 0% (co-
twin) suffered an IUD following expectant, laser and selective termination. In type II sFGR, 
16.6%, 44.3%, and 5% (co-twin) experienced an IUD following the above treatments 
respectively, and 89.3%, 100%, and 90.6% were free of neurological sequelae (Figure 3). In 
type III sFGR, 13.2%, 32.9%, 0% (co-twin) had an IUD after these treatments, and 61.9%, 
100%, and 98.8% had intact neurology37. This shows that the severe cases may benefit from 
intervention to reduce perinatal morbidity, however, the evidence is largely based on 
observational studies.  
Despite the fact that Gratacos classification has been used since its publication in 2007, 
debate exists regarding whether a modification is needed as it does not take into account the 
gestational age (GA) at diagnosis, the variation in the UA Doppler in the smaller twin 
especially at early gestation, the ductus venosus (DV) Doppler or the co-existence of TTTS 
or event of IUD of the smaller twin. In a cohort study of MCDA twin pregnancies followed 
from the first trimester until birth, in early-onset (<24 weeks’ gestation) cases, the incidence 
of Types I, II and III sFGR were 81%, 15% and 4%, respectively (Figure 4). In late-onset 
(≥24 weeks) cases, the corresponding figures were 94%, 6% and 0%. The incidence of 
superimposed TTTS was 27% in cases affected by early-onset sFGR compared with 6% in 
those with late-onset sFGR32. Therefore, GA at diagnosis influences the incidence, types 
and prognosis of sFGR and should be taken into account. Several studies have reported that 
DV Doppler is an independent predictor of the risk of demise of the smaller or the larger 
twin38,39. This supports its incorporation in a staging or a classification system of sFGR. 
Moreover, despite the fact that the presence of TTTS is not an independent predictor of the 
risk of demise, it does alter management and represents an urgent need for intervention38,39.  
A modified classification of sFGR in MC twin pregnancies is proposed in Box 1 and Figure 5. 
sFGR is classified into early and late-onset, as well into stages taking into account the UA 
and DV Dopplers, presence of TTTS, and IUD of the smaller twin (Box 1 and Figure 5). 
Future studies are required to validate this proposed classification and assess its prognostic 
value. 
After 26 weeks’ gestation, early delivery after a course of steroids can be considered in the 
case of severe sFGR, where the risks of stillbirth and co-twin morbidity outweighs those of 
prematurity35. In DC twins however, the risks to the AGA twin is lower following co-twin 
demise, therefore, conservative management with careful monitoring is preferable. The 
decision for delivery should be made after thorough counselling on a case-by-case basis, 
taking into account the risks versus benefits, and is generally not recommended in DC twin 
before 30 weeks’ gestation9.  
The development of a standardised diagnostic criteria and national guidance on surveillance 
protocols has the potential to improve the diagnosis and monitoring of sFGR. The optimal 
antenatal intervention and timing of delivery in sFGR continues to pose a conundrum, 
therefore more robust research is required to establish a management with the most 
favourable outcome. 
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Controversies in the management of TTTS 
The diagnosis of TTTS is based on a sonographic amniotic fluid discordance in the form of 
polyhydramnios oligohydramnios sequence (DVP ≥10cm after 20 weeks or ≥8cm before 20 
weeks in the recipient twin, with a DVP ≤2cm in the donor twin)9. In the earlier gestations 
however (16-18 weeks), the normal range for amniotic fluid is lower (90th centile 6cm at 16-
17 weeks)40, possibly due to the fact that fetal urine is not the main constituent of amniotic 
fluid at that gestation. It may therefore be argued that the diagnostic criteria is modified to 
lower the threshold for classifying polyhydramnios at the earlier gestations to 6cm, in order 
to avoid misdiagnoses and poor outcomes as a result of missed intervention (Figure 6)41.  
Various research have attempted to establish first trimester ultrasound signs or maternal 
characteristics predictive of adverse perinatal outcomes in MC twins, such as TTTS42,43. 
However, recent meta-analysis has suggested that it is currently not possible to detect these 
complications in the first trimester scan44, limiting the detection and screening for TTTS to 2 
weekly scans from 16 weeks9,21,25. Amniotic fluid discordance not fulfilling the diagnosis of 
TTTS generally have a good prognosis, with an overall survival rate of 93%45, but is at an 
increased risk of developing TTTS, particularly if the discordance is >3.1cm before 20 
weeks46. Therefore, it is recommended that MC twins with an amniotic fluid discordance 
(DVP) of ≥4cm should be monitored by ultrasound at least weekly, with the addition of UA 
Dopplers9,21.  
Fetoscopic laser photocoagulation is the recommended treatment for Quintero stage 2 or 
above, before 26 weeks9, as the long-term neurodevelopmental outcome is superior to those 
who underwent amniodrainage47. Traditionally, laser was avoided before 16 and after 26 
weeks, due to the lack of fusion between the chorion and amnion in the early gestations, and 
the poor visibility after 26 weeks. However, Baud et al found that laser treatments performed 
at these early and late gestations yielded similar outcomes to those done at 16-26 weeks, 
with no added complications48. Nevertheless, amniodrainage is a well-recognised treatment 
option for late TTTS9, and when compared with laser, did not yield a higher rate of overall 
fetal or neonatal death47. The management for Quintero stage 1 remains controversial. 
Conservative management with intensive monitoring can be considered, in the absence of 
cervical shortening or maternal discomfort9, and evidence from a meta-analysis of stage 1 
TTTS has shown a similar rate of survival of at least one twin in those expectantly managed 
(87%, 95% CI 69-98%), underwent amniodrainage (86%, 95% CI 76-94%), and those who 
received laser photocoagulation (81%, 95% CI 69-90%), with a progression rate of 27% 
(95% CI 16-39)49. Furthermore, the North American Fetal Therapy Network found that both 
amniodrainage (OR 0.11, 95% CI 0.02-0.68) and laser photocoagulation (OR 0.07, 95% CI 
0.01-0.37) reduced the risk of no survivors, and that laser was in fact protective against poor 
outcomes (OR 0.12, 95% CI 0.03-0.44)50. 
Post laser, it is common practice to perform weekly scans for the first 2 weeks, and if clinical 
resolution is evident, 2 weekly scans can be resumed. In cases of sIUD, fetal brain MRI 
should be considered 4-6 weeks post demise to exclude neurological injury9. The timing of 
delivery post laser for TTTS is debatable. It is commonly scheduled by 34 weeks, due to the 
evidence that the risk for perinatal death or severe brain injury significantly declines if 
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delivered after 34 weeks (35% 26-28 weeks vs 3% 34-36 weeks)51, but it may be argued that 
in the absence of further pathology, delivery can be postponed until 37 weeks9. 
Although the diagnosis and treatment of TTTS have been supported by robust evidence, the 
diagnostic criteria for early TTTS, and the management of early and late TTTS, as well as 
Quintero stage 1 TTTS, remains controversial.  
 
Controversies in the management of TAPS 
TAPS, originally described in 2006, remains open to numerous controversies. The standard 
antenatal diagnostic criteria of MCA PSV >1.5MoM in the donor and <1.0MoM in the 
recipient was found to have a sensitivity of 46%, specificity of 100%, with positive and 
negative predictive values (PPV and NPV) of 100% and 70% respectively52. Recent studies 
found that recipient twins with an MCA PSV >1.0MoM could still be polycythaemic at birth, 
therefore proposed an alternative diagnostic criterion using delta PSV as opposed to the 
traditional cut offs, providing a stronger predictor of haemoglobin discordance at birth53. So 
far, research has proposed delta PSV criteria of >0.5MoM52 and >0.373MoM54, both with 
increased sensitivity (83% and 93% respectively) and NPV (88% and 99% respectively) 
compared to the traditional diagnostic criteria, but a lower PPV, which can lead to over 
diagnosis (Table 1). A Delphi consensus was also carried out to establish unified criteria, 
where experts felt that an MCA PSV cut off of >1.5MoM and <0.8MoM in the donor and 
recipient, or a delta PSV of >1.0MoM should be used to achieve an antenatal diagnosis of 
TAPS (Figure 7)55. The criteria with the most optimal detection and outcome with the least 
unnecessary intervention are yet to be established.  
The ISUOG guideline recommends 2 weekly screening for TAPS through MCA PSV 
measurements in all MC pregnancies9. However, due to the controversies and lack of 
evidence in its management, many clinicians felt that it was more appropriate to only perform 
this screening in those with high risk pregnancies (e.g. post laser for TTTS)21,25. TAPS can 
develop spontaneously or post laser, however, the natural history and outcomes can be 
variable, ranging from rapid progression and double IUD to stable/slow progression and the 
birth of 2 healthy babies with discordant haemoglobin. Long-term neurodevelopmental 
outcomes of those babies who developed TAPS post laser have suggested a 9% 
neurodevelopmental impairment, and a 17% mild-moderate cognitive delay56, whereas this 
delay was proposed to be higher in spontaneous TAPS survivors (26%)57.  
Management options include conservative management, intrauterine transfusion/partial 
exchange transfusion, laser photocoagulation, selective termination, or early delivery. 
Currently, there is no consensus on the most superior method of management. The 
treatment of choice depends on the gestation at diagnosis, disease progression or severity, 
access or feasibility of intrauterine intervention, and maternal choice, and therefore should 
be made on an individualised basis following thorough counselling9. 
 
Controversies in the management of TRAP sequence 
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Twin reversed arterial perfusion (TRAP) sequence can lead to a 33% risk of IUD of the pump 
twin if managed conservatively before 18 weeks58, and following this, the risk of perinatal 
mortality of the surviving pump twin is stated to be 55%59. In an observational study of 26 
pregnancies with TRAP sequence, where 2 underwent termination of pregnancy, 21% had 
spontaneous resolution of flow to the acardiac twin, and 46% had persistent flow58. 
Treatments include intrafetal laser or cord coagulation, where it was found that the intrafetal 
techniques were associated with a later gestation at delivery (37 vs 32 weeks, p=0.04), a 
higher success rate (77% vs 50%, p=0.02), and a lower preterm rupture of membranes or 
delivery rate (23% vs 58%, p=0.003), with an 80% overall survival of the pump twin following 
intervention60. Traditionally, these procedures were carried out after 16 weeks, due to the 
separation of the membranes by the exocoelomic cavity, particularly if there was evidence of 
cardiac strain of the pump twin, or increased perfusion, growth of the TRAP mass, or 
polyhydramnios9. However, it was suggested by more recent evidence that treatment prior to 
16 weeks was associated with a significantly lower rate of adverse outcome (19% vs 66%, 
p=0.003)61. Furthermore, a later meta-analysis revealed that there was an inverse 
relationship between the gestation at treatment and gestation at birth62. Therefore, this led to 
the development of the TRAP Intervention Study (TRAPIST), which is a multi-centre 
randomised controlled trial aiming to compare whether early intervention (12-14 weeks) 
improves the outcomes of TRAP sequence compared to late intervention (16-18 weeks), and 
is currently still ongoing (https://clinicaltrials.gov/ct2/show/NCT02621645).  
In those pregnancies that had a late diagnosis of TRAP sequence, or did not wish for 
intervention, close serial ultrasound monitoring should take place by a fetal medicine 
specialist, for signs of cardiac decompensation and hydrops in the pump twin. Due to the 
likely development of polyhydramnios around the TRAP mass, preterm delivery prior to 32 
weeks is increased at 10%61. There is currently no consensus on the timing of birth in TRAP 
sequence following expectant or active management, therefore, an individualised approach 
should be taken based on the success of treatment, fetal Dopplers, and cardiac stability of 
the pump twin.  
 
Controversies in the management of MCMA twin pregnancies 
Monochorionic monoamniotic (MCMA) twin pregnancies are at increased risk of perinatal 
mortality, with rates quoted as high as 50% from the first trimester ultrasound, largely due to 
congenital anomalies and spontaneous miscarriage63. Previously, cord entanglement leading 
to vascular injury was thought to play a major role in the cause of IUD, however, more recent 
evidence have shown that not only is cord entanglement present in almost all MCMA twins64, 
but does not contribute to the increased perinatal mortality rate65.  
Antenatal management of MCMA twins have been controversial. Whilst some may suggest 
inpatient monitoring with regular fetal monitoring is beneficial, others suggest that this does 
not influence perinatal outcome66. A recent meta-analysis showed that inpatient monitoring 
had a 3% risk of IUD (95% CI 1.4-5.2%), where outpatient management had a higher IUD 
risk of 7.4% (95% CI 4.4-11.1%)67. However, a multicentre cohort study observed no 
significant difference in perinatal mortality between the inpatient and outpatient managed 
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groups of MCMA twins (adjusted OR 0.21, 95% CI 0.04-1.17)68. Recommendations on 
timing of birth have varied between 32-36 weeks. However, recent evidence suggests that 
early delivery is warranted due to the higher risks than other twin pregnancies, and the fact 
that the risk of fetal demise from 32 weeks and 4 days exceeded the risk of non-respiratory 
neonatal complications69. The fore mentioned meta-analysis also found that the highest risk 
of IUD after 24 weeks was 24-30 weeks (4.3%, 95% CI 2.8-6.2%), which reduced to 1% at 
31-32 weeks (95% CI 0.6-1.7%), and doubled to 2.2% at 33-34 weeks (95% CI 0.9-3.9%)67. 
it was felt that MCMA twins should be delivered between 32-33 weeks9,21.  
 
Controversies in screening and prevention of preeclampsia in twins 
Screening and prevention of preeclampsia has revolutionised following the publication of the 
Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for 
Evidence-Based Preeclampsia Prevention (ASPRE) trial. By using a combination of 
maternal risk factors, serum biochemistry, mean arterial pressure (MAP), and uterine artery 
Doppler, a risk for developing preterm preeclampsia was stratified and those high risk were 
randomised to treatment with Aspirin or placebo. This screening tool found that the detection 
rate of preterm preeclampsia was 77%, with a reduction of 62% in those treated with 
Aspirin70. This trial however, was only limited to singleton pregnancies, despite the higher 
risk of preeclampsia in multiple pregnancies. Based on a low risk population derived from 
maternal characteristics (Caucasian, height 164cm, weight 69kg, no family or medical 
history), the risk of preeclampsia <37 weeks was 0.6% in singletons, 9% in DC twins, and 
14.2% in MC twins71. Studies since have assessed the application of the same screening 
tool in twins, which concluded that although this methodology can be applied in twins, a high 
detection rate would also require a very high screen-positive rate (SPR)72.  
Furthermore, the majority of twins are recommended aspirin prophylaxis if there are any 
additional risk factors such as nulliparity73, but the role of aspirin in preeclampsia prevention 
in multiple pregnancies is yet to be established. Following the finding that aspirin dosage 
exceeding 100mg was more beneficial than 75mg from an individual patient data (IPD) 
analysis74, the dose of 150mg daily began to be more favourably used. A recent study 
compared the traditional dose of 75mg with the newly recommended dose of 150mg in 
twins, and found that those who took 150mg daily had a significantly lower rate of 
preeclampsia (1.8% vs 11.1%, p=0.003), but the rate of preeclampsia between the 150mg 
and no aspirin groups saw no significant difference75. Therefore, the role in preeclampsia 
screening in twins remains controversial, given the insufficient evidence for aspirin in 
prevention, and the high SPR required achieving a good detection rate. 
 
Controversies in the management of single intrauterine demise in twins 
The impact on the co-twin following sIUD differs depending on chorionicity. In MC twins, the 
shared circulation leads to hypovolaemic shock to the co-twin, resulting in higher rates of co-
twin demise and neurological injury, together with a risk of fetal anemia. This is supported by 
a meta-analysis which demonstrated that co-twin death following sIUD was 3% in DC and 
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15% in MC twins, preterm birth 54% in DC twins and 68% in MC twins, and neurological 
impairment 2% in DC twins vs 26% in MC twins30. Management of the pregnancy following 
this event is largely dependent on the chorionicity and gestation at the time of sIUD. 
Evidence has shown that the gestation at sIUD is inversely related to the gestation at 
delivery76, and that co-twins are less likely to suffer neurological morbidity if the sIUD 
occurred after 34 weeks in MC twins, which may be due to a lower risk of prematurity at that 
gestation30.   
Immediate delivery is not advisable if the death occurs prematurely, as the injury to the co-
twin has likely already occurred, it would be reasonable to conservatively monitor the co-twin 
to minimise the risk of iatrogenic prematurity9. Patients should be referred to a fetal medicine 
centre with the relevant expertise for counselling and monitoring. Two weekly scans should 
be scheduled together with growth and Doppler assessments for MC twins, in particular the 
MCA PSV to detect signs of fetal anaemia77, and 4 weekly scans for DC twins9. Fetal brain 
imaging should be performed 4-6 weeks post sIUD, and delivery should be considered at 34-
36 weeks following a course of steroids for lung maturity9.  The recommended gestation to 
deliver these pregnancies is also controversial, with some clinicians advocating expectant 
management until term.  
 
Controversies in the management of discordant anomalies 
Discordant anomalies can complicate 1-2% of twins9, where only one twin is affected by an 
anomaly in 80% of cases78. Whilst genetic discordance is rare in MC twins, heterokaryotypic 
MC twins with discordant aneuploidies have been reported79. Prenatal invasive testing can 
be offered following diagnosis of these anomalies, where earlier diagnosis is preferred due 
to lower risks of pregnancy loss and preterm delivery when selective termination is 
performed in the first trimester compared to the second trimester (7% entire pregnancy loss, 
14% preterm delivery)80. In DC twins, CVS sampling of both placentas is recommended, 
whilst in MC twins, sampling the single placenta may miss rare cases of discordant 
aneuploidies, therefore, amniocentesis of both sacs should be considered when technically 
feasible9.  
The decision for expectant management or selective termination can pose a clinical 
dilemma. The risk of sIUD of the discordant twin can result in serious consequences for the 
normal twin, particularly in MC pregnancies. Counselling regarding management should 
involve careful consideration of the nature of the abnormality (lethal or non-lethal), patient 
choices, gestational age and chorionicity. Women with lethal abnormalities may be 
counselled regarding the option of palliative care of the abnormal twin after birth, whilst those 
with non-lethal abnormalities wishing to discontinue the pregnancy may prefer the option of 
selective termination. 
In DC twins, intrathoracic or intracardiac injection of Potassium Chloride (KCl) can be 
performed, whilst due to the shared circulation in MC twins, this procedure would be 
contraindicated. Therefore, methods of cord occlusion, intrafetal laser ablation, or 
radiofrequency ablation (RFA) would be preferred81, 82. In cases of diagnosis after the first 
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trimester, selective termination in the third trimester will only expose the healthy twin to the 
risk of preterm birth, ameliorating the added risk of a second trimester miscarriage, 
therefore, would be a more desirable option9. However, this may be technically challenging 
to perform in MC twins due to an increased thickness of the umbilical cord, therefore, some 
clinicians may prefer to perform these procedures in the second trimester due to technical 
feasibility, with a reported co-twin survival rate of 83%79. A recent cohort study evaluated the 
outcomes of the healthy co-twins in groups of discordant MC twins undergoing expectant 
management versus selective fetocide, and found that no significant differences in livebirth 
rates were seen with either form of management (88.5% expectant management, 82.7% 
selective fetocide, p=0.87)83. Therefore, the management of discordant anomalies remain 
controversial, and requires careful counselling and treatment planning with consideration of 
patient wishes. 
 
Controversies in the screening, prevention, and management of preterm birth in twins 
Twin pregnancies are at significantly higher risk of preterm delivery than singletons, where 
more than half is likely to deliver before 37 weeks, and 15% prior to 34 weeks84. Despite the 
proven benefits of progesterone and cerclage placement in preventing preterm delivery in 
high risk singletons, these treatments have not shown similar effects in twin pregnancies85, 
86. The benefits of screening for those at risk of preterm labour remain controversial. Fetal 
fibronectin assessments have been shown to be of minimal to moderate predictive value for 
preterm birth in twins87. Cervical length screening through transvaginal ultrasound 
measurements is likely to be a good predictor of preterm birth in asymptomatic women, with 
a positive likelihood ratio of 10.1 in predicting birth <32 weeks and 9.0 <34 weeks if the 
cervical length is found to be ≤20mm at 20-24 weeks, and a positive likelihood ratio of 9.6 in 
predicting birth <28 weeks if the cervix was ≤25mm at the same gestation88,89. A meta-
analysis of IPD showed that vaginal progesterone use in those with a sonographically short 
cervix can reduce the risk of preterm birth and perinatal morbidity and mortality90. Despite 
this, it was felt that the benefits of preventative treatment are yet to be ascertained and that 
that the evidence was not robust enough to justify recommendation of ultrasound 
screening21, therefore, routine cervical length measurements is still under debate. 
Cervical cerclage in twin pregnancies with a short cervix has received conflicting evidence, 
where it was originally believed to be associated with a significantly increased risk of preterm 
birth91. Some studies have shown a potential benefit of emergency cerclage in twins with a 
short or open cervix, with an increased interval to delivery of 71-92 days92-94, but these 
studies were largely observational. The only RCT included only 7 twins, where they found a 
significant decreased risk of preterm birth <34 weeks and a longer interval from diagnosis to 
delivery (30 days) in the cerclage group than bed-rest alone, but these results were reported 
together with the singleton pregnancies95. This potential benefit in emergency cerclage in 
twins was further supported by a recent meta-analysis96. However, critics demonstrated that 
the results derived from the randomised trials showed that cerclage was in fact associated 
with increased preterm birth and poor perinatal outcome, but in those with a short cervix97. In 
view of the numerous controversies, the Emergency Cerclage in Twin Pregnancies at 
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Imminent Risk of Preterm Birth (ENCIRCLE) trial was created. This is a multi-centre, open-
label RCT, inclusive of twins 16-26 weeks with symptomatic open cervix, where they are 
randomised to cerclage or conservative management 
(https://clinicaltrials.gov/ct2/show/NCT03818867).  
The management of preterm labor in twins pose a further challenge to clinicians. Preterm 
prelabor rupture of membranes (PPROM) in one twin can predispose to chorioamnionitis, 
but early delivery could also jeopardise the wellbeing of the other twin, exposing them to 
iatrogenic preterm delivery. A systematic review of 128 twin pregnancies where one twin 
underwent preterm delivery, and the second twin was conservatively managed with delayed-
interval delivery showed that the mortality of the second twin was significantly lower than the 
first (relative risk (RR) 0.44, 95% CI 0.34-0.57, p<0.001). The same review however found 
that 28 out of 90 women developed chorioamnionitis98. Outcomes can also differ depending 
on the twin exposed to PPROM, where a longer latency period (41.3 vs 10.1 days from 
PPROM to delivery, p<0.05) and fewer neonatal deaths (0% vs 21.4%, p=0.05), if PPROM 
occurred in the non-presenting twin99. Therefore, conservative management following 
preterm delivery of twin 1 can be considered in a carefully selected population in order to 
improve outcome for twin 2.  
Fetal monitoring in labor in preterm twins should be performed in the form of a continuous 
CTG from 26 weeks, with an ultrasound scan to located the separate fetal hearts prior to 
monitoring21. Lower gestations may be more difficult to monitor through CTG surveillance, 
therefore a discussion should take place with a senior Obstetrician with the family regarding 
the mode and frequency of monitoring21.  
Mode of delivery (MOD) in preterm twins (24-33 weeks) and their outcomes were analysed 
by the Canadian Neonatal Network in 3318 sets of twins. Caesarean section (CS) was found 
to have a lower rate of severe neurological injury (adjusted OR 0.77, 95% CI 0.61-0.98), but 
higher rate of respiratory distress syndrome (RDS) (adjusted OR 1.34, 95% CI 1.15-1.56)100. 
This is also supported by an earlier study of 4428 sets of twins weighing 500g or more, 
which found that neonatal mortality and low Apgar scores were lower in babies weighing 
500-749g who underwent a CS (p<0.05), where this protective benefit was not observed in 
babies weighing >1000g101. Furthermore, a systematic review found that preterm breech 
babies had a significantly lower mortality rate if a CS was performed (3.8% vs 11.5% in 
vaginal birth)102. Therefore, it has been recommended that preterm twins labouring between 
26-32 weeks with a non-cephalic presenting twin should be offered a CS21.  
 
Controversies in the timing of birth in uncomplicated twin pregnancy 
Twin pregnancies are dated according to the crown rump length (CRL) measurement of the 
larger twin at the 11-13+6 week scan9. Some studies suggested that the CRL of the smaller 
twin may be more accurate103, but as this can give false reassurance that the smaller twin is 
growing appropriately, leading to a missed diagnosis of aneuploidy or sFGR, this method is 
not commonly used in practice.  
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In DC twins, the main cause of late IUD is thought to be due to FGR104, where the IUD risk at 
36-37 already equates to those of post-mature singletons105, and significantly increases at 
38-39 weeks106. According to a recent meta-analysis, if delivered at 36 weeks, the risk of 
neonatal death (NND) was higher than IUD (3.2 vs 1.5:1000), whereas this becomes 
inversed from 37 weeks, where the risk of IUD overtakes that of NND (3.4 vs 2.2:1000)107, 
leading to the common practice of delivering DC twins from 37 weeks21. 
In MCDA twins, the risk of IUD is significantly higher than that of DC twins (19.1 vs 6.5:1000 
after 26 weeks)108, largely due to the MC specific complications. This risk begins to increase 
from 32 weeks, and further still from 36 weeks104, when the risk of composite neonatal 
morbidity is observed to fall109. It was also found that at 35 weeks, the risk of NND was 
significantly higher than IUD (8.1 vs 2.8:1000), which sees a reversal in its relationship from 
37 weeks, when the risk of IUD becomes greater than that of NND (9.6 vs 3.6:1000)107. 
Therefore, it is commonly recommended that MCDA twins are delivered between 36-37 
weeks21. The timing of birth in MCMA twins is covered in an earlier section of this paper. 
 
 
 
Role of steroids in twin pregnancy 
Numerous RCTs in singleton pregnancies have shown that a course of maternal antenatal 
corticosteroids can reduce perinatal death, respiratory distress syndrome (RDS), 
intraventricular haemorrhage (IVH), and necrotising enterocolitis, in those with preterm birth 
below 34 weeks110. Its use is routinely recommended in singletons undergoing preterm birth 
below 34 weeks111,112. According the Cochrane database review, previously reported 
maternal adverse effects such as chorioamnionitis and endometritis were not shown to be 
increased by steroids, nor were factors such as neurodevelopmental delay or birthweight 
influenced110. However, there remains a risk of maternal hyperglycaemia, particular in those 
mothers with diabetes, resulting in neonatal hypogycaemia113.  
Twelve studies included twins in the Cochrane review, which did not suggest a significant 
difference in its benefit than shown in singletons, but only 4 of these studies reported the 
outcomes in twins separately, and all were outdated110. Nevertheless, some guidelines 
recommended the use of steroids in twins labouring before 34 weeks as similar benefits 
were demonstrated112,114. More recent studies have since compared the effects of steroids 
between twins and singletons, with conflicting findings. A large cohort study found that twins 
showed a similar reduction in short term respiratory morbidity, neonatal death, and 
neurological injury as singletons when steroids were given 1-7 days before birth, but no 
reduction in the other morbidities115. This reduction in respiratory morbidity was supported by 
a more recent study116, but was contradicted by others, where they observed no such 
improvement in short term morbidities, but possibly a reduction in neonatal mortality117,118. A 
proposed explanation to the questionable benefit of steroids in twins may be due to a shorter 
half-life of betamethasone observed in mothers of twins (7.2 +/- 2.4 vs 9.0 +/- 2.7 hours, 
p=0.017)119. 
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More recently, evidence have also shown in singletons that steroids at term (at or after 37 
weeks) can reduce the risk of RDS, transient tachypnoea of the neonate (TTN), and NNU 
admissions in those undergoing planned CS120,121. Data on the benefit of steroids on twins at 
this later gestation however, is scarce, therefore the use of steroids at or near team remains 
under debate. The Effects of antenatal Corticosteroids in Twin neonates with late preterm 
birth (ACTWIN) trial is an RCT that is currently underway to compare the benefit of steroids 
vs placebo in twins with late preterm labour at 34-36+5 weeks 
(https://www.clinicaltrials.gov/ct2/show/NCT03547791)122. 
 
Mode of delivery in twin pregnancy 
Mode of delivery in twins have been open to numerous controversies in the literature. Whilst 
older studies did not show any significant associations between the birth order and mode of 
delivery with perinatal deaths, Smith et al have demonstrated through a large retrospective 
cohort study that second twins were in fact at a significantly higher risk of perinatal death 
than the first twins when delivered vaginally (OR 1.16, 95% CI 1.01-1.35, p=0.04), whereas 
those who underwent CS did not have any delivery rated deaths123. The same authors went 
on to analyse the outcomes of a larger cohort of term twins over 36 weeks (n=8073), and 
found that those who had a planned CS had a significantly lower rate of death than other 
deliveries (OR planned CS 0.26, 95% CI 0.03-1.03, p=0.05). They also found that the 
second twin had a higher rate of intrapartum anoxia compared to the first twin (OR 21, 95% 
CI 3.4-868.5), as well as a higher death rate (OR 5.00, 95% CI 2.00-15.7)124. The Twin Birth 
Study randomised 2804 women at 32-38+6 weeks with a cephalic presenting twin to vaginal 
or Caesarean delivery. This RCT found no significant difference in the rate of neonatal 
mortality or serious morbidities in the planned CS or vaginal delivery groups (2.2% vs 1.9% 
respectively, OR 1.16, 95% CI 0.77-1.74, p=0.49). They did find however that 43.8% of 
those who planned a vaginal delivery went on to deliver by CS125. The mode of birth in very 
preterm twins is covered in an earlier part of this paper. 
This led to an update in the NICE guidelines in twin and triplet pregnancies, where women 
should be informed that both vaginal or CS deliveries are safe, provided they have 
uncomplicated pregnancies, the presenting twin is cephalic, there are no large size 
discrepancies, or other contraindications for labor21. 
 
Core outcomes in twins 
It has come to the attention of researchers that in order to increase the value of research 
and to adequately reflect the disease impact and the risks and benefits of treatments, 
outcomes should be defined and reported in a standardised fashion126. It was demonstrated 
in a systematic review of 100 studies on TTTS that 62 different outcomes were reported, 
with only a very limited focus on neonatal morbidity127. Therefore, the International 
Collaboration to Harmonise Outcomes for Twin-Twin Transfusion Syndrome (CHOOSE) set 
out to establish a core outcome set of essential reported outcomes in TTTS, in order to 
advance the effectiveness of research into this area. This was performed using a 3-round 
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Delphi survey involving 103 participants from 29 countries, and a final consensus meeting, 
formed of clinicians, patients and researchers. Twelve final core outcomes were decided 
which included a combination of antenatal complications, fetal, neonatal, and maternal 
outcomes128. Similarly, in sFGR 96 different outcomes were found from 36 studies in a 
systematic review, therefore, the same group felt that it was important to standardise 
outcome reporting in this condition (CHOOSE-FGR). This was also performed using a step-
wise approach inclusive of participants from different multidisciplinary perspectives, as well 
as patients themselves, leading to a concluding set of 11 core outcomes to aid with future 
research reporting129. 
 
Twin and Multiples Priority Setting Partnership 
The numerous controversies and research needs in twin and multiple pregnancies have led 
a group of experts and patient representatives to come together to form the Global Twins 
and Multiples Priority Setting Partnership (PSP), whose common goal was to establish the 
10 most important research uncertainties in multiple pregnancies, and thereby improving the 
health and social outcomes for multiples and their families. Following the James Lind 
Alliance method130, a steering group of 32 experts from various cultural and professional 
backgrounds designed an online survey asking participants for their top 3 unanswered 
research questions in this field. This received an overwhelming response from 1120 
participants from 31 countries, who suggested 2891 research uncertainties. After the 
removal of duplicates and classification into indicative questions in 5 categories, 235 
quantitative and 455 qualitative questions were found. Focusing on the quantitative 
questions, a guideline and literature search was performed and 89 remained unanswered by 
robust evidence, and the qualitative questions were decided to be analysed at a later stage. 
A second round of surveys with the 89 unanswered questions was redistributed for the 
participants to select the top 3 from each category. The final questions were taken to the 
final workshop, consisting of 23 participants (clinicians, researchers, patients), and the top 
10 research priorities were chosen (Box 2)131. 
Conclusions 
Twin pregnancies pose a multitude of challenges and controversies as outlined in this paper. 
Many issues on classification and management remain under debate. Efforts on 
standardising diagnostic criteria, outcome reporting, and the development of national and 
international practice guidelines will help in research effectiveness and clinical practice. The 
Twin and Multiples PSP have also elicited the top 10 most pressing research uncertainties 
identified by both clinicians and patients. Nevertheless, more robust research in the form of 
RCTs or large well-conducted cohort studies are still required to ameliorate many of these 
controversies, in order to enable the most optimal care and further improve the outcomes in 
twin pregnancies. 
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FIGURE LEGENDS 
Figure 1. Diagnostic criteria of selective fetal growth restriction in twin pregnancy: 
International consensus 
 
Figure 2. The classification of selective fetal growth restriction in monochorionic twin 
pregnancies. In type I the umbilical artery Doppler waveform has positive end-diastolic flow, 
while in type II there is absent or reversed end-diastolic flow (AREDF).  In type III there is a 
cyclical/intermittent pattern of AREDF.   
 
Figure 3. Perinatal outcomes (intrauterine demise 3a and intact survival 3b) following 
expectant management, fetoscopic laser photocoagulation, and selective termination in 
monochorionic twin pregnancies complicated by selective fetal growth restriction according 
to Gratacós classification. 
 
Figure 4. Incidence and type of selective fetal growth restriction in monochorionic twin 
pregnancy according to the gestational age at diagnosis.  
 
Figure 5. Modified classification of selective fetal growth restriction in monochorionic twin 
pregnancy 
 
Figure 6. Modified diagnostic criteria of twin-to-twin transfusion syndrome 
 
Figure 7. Diagnostic criteria of twin anemia polycythemia sequence: International consensus 
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Table 1. Predictive accuracy of various diagnostic criteria of twin anemia polycythemia sequence 
Diagnostic criteria Sensitivity Specificity 
Positive 
predictive value 
Negative 
predictive value 
MCA PSV >1.5MoM + <1MoM 46 100 100 70 
MCA PSV delta ≥0.5MoM 83 100 100 88 
MCA PSV delta ≥0.373MoM 93 96 70 99 
 
All the values are percentages. 
MCA: middle cerebral artery; PSV: peak systolic velocity; MoM: multiple of median 
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Box 1. Modified classification of selective fetal growth restriction in monochorionic twin 
pregnancy 
 
 
 
 
 
 
 
  
Selective Fetal Growth Restriction in Monochorionic Twin Pregnancy: New Classification  
According to the gestational age at diagnosis: 
• Early-onset (<24 weeks) 
• Late-onset (≥24 weeks) 
According to the umbilical artery, ductus venosus Doppler and co-existing TTTS: 
• Stage 1: umbilical artery Doppler positive EDF in the smaller twin 
• Stage 2:  
• 2a:umbilical artery Doppler persistent AREDF in smaller twin 
• 2b: umbilical artery Doppler intermittent AREDF in the smaller twin 
• Stage 3: abnormal ductus venosus Doppler in the smaller twin 
• Stage 3: superimposed twin-to-twin transfusion syndrome 
• Stage 5: intrauterine demise of the smaller twin 
*Stage 3 and 4: recommend intervention 
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Box 2. Top 10 research questions according to the Global Twins and Multiples Priority 
Setting Partnership (PSP) 
 
  
 
1. Would staff with specialist training in multiple pregnancies improve outcomes in these 
pregnancies?  
2. How can we reduce multiples’ admission to the neonatal unit? If admitted, how can we 
reduce multiples’ length of stay in the neonatal unit?  
3. What interventions prevent and support postnatal mental-health problems in parents of 
multiples?  
4. How can we prevent maternal complications in multiple pregnancies?  
5. What are the short- and long-term outcomes in multiple pregnancies? How are these 
outcomes affected by antenatal events and medical interventions?  
6. How are higher-order multiple pregnancies best managed?  
7. What are the expected growth patterns of small-for gestational-age multiples? How can 
we assess the growth of infant multiples and ensure that they follow a satisfactory growth 
trajectory?  
8. What parental interventions can improve the developmental outcomes (i.e. speech, 
language, education) of multiples?  
9. What are the short- and long-term maternal health risks following a multiple pregnancy?  
10. What prenatal factors (including changes to lifestyle, health history, personality 
characteristics) and supports for parents of multiples have the most benefit on birth and 
ongoing health outcomes for both parents and their children?  
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